Compare Becton Dickinson and Co (BDX) vs ProShares UltraPro Short QQQ ETF (SQQQ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Becton Dickinson and Co vs ProShares UltraPro Short QQQ ETF — how do they compare? Becton Dickinson and Co trades at $179.18 (market cap $49.41B), while ProShares UltraPro Short QQQ ETF trades at $37.24. The key difference: Becton Dickinson and Co pays a 2.32% dividend while ProShares UltraPro Short QQQ ETF pays none, and Becton Dickinson and Co is trading nearer its 52-week high, ProShares UltraPro Short QQQ ETF nearer its low. Which is the better fit depends on your goals.
| BDX | SQQQ | |
|---|---|---|
Market Cap | $49.41B | — |
Sector | Health | Leveraged / Inverse |
52-Week High | $185.39 | $92.95 |
52-Week Low | $138.62 | $36.31 |
Enterprise Value | $65.51B | — |
Dividend Yield | 2.32% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BDX trades at $179.63, up 1.57% with a bullish technical outlook supported by moving averages. The company reported strong Q3 2026 earnings, beating estimates with $3.23 EPS versus $3.14 expected, and raised full-year guidance. Revenue growth remains steady at 4.4% FX-neutral, though margins face pressure from tariffs. Analysts maintain a mixed consensus with 47% buy ratings and a $183 price target, suggesting modest upside from current levels.
The stock presents a balanced opportunity with solid fundamentals and dividend stability, but faces headwinds from margin compression and competitive pressures. Near-term catalysts include continued execution on growth initiatives, while risks include tariff impacts and healthcare regulatory changes. The current valuation at 31.39 P/E appears fair given growth prospects.
SQQQ, a 3x leveraged inverse ETF tracking the Nasdaq-100, trades at $37.15, down 1.56% on the day. Technical indicators are bearish overall, with moving averages signaling selling pressure, though oscillators are neutral. The ETF is designed for short-term tactical use, not long-term holding, due to daily resets that erode value over time.
The outlook for SQQQ is highly speculative, offering potential gains if the Nasdaq-100 declines, but risks are severe, including rapid decay from leverage and volatility decay. It may serve as a hedge for QQQ holdings but is unsuitable as a standalone investment given its long-term performance history of significant losses.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Becton Dickinson and Co
Becton, Dickinson is the world's largest manufacturer and distributor of medical surgical products, such as needles, syringes, and sharps-disposal units. The company also manufactures diagnostic instruments and reagents, as well as flow cytometry and cell-imaging systems. BD Interventional (largely the former Bard business) accounts for 23% of revenue. International revenue accounts for 44% of the company's business.
Read more on BDX →About ProShares UltraPro Short QQQ ETF
SQQQ is a leveraged inverse ETF that seeks daily investment results, before fees and expenses, that correspond to three times the inverse (-3x) of the daily performance of the Nasdaq-100 Index. It is a tactical trading tool designed for sophisticated investors to profit from or hedge against declines in large-cap technology and growth stocks. Due to its daily reset and the effects of compounding, it is intended for short-term use and carries significant risk if held during periods of high market volatility.
Read more on SQQQ →
